What Happened
Eli Lilly and Hims & Hers announced an agreement on November 6 that places two FDA-approved Lilly obesity medicines — the injectable Zepbound (tirzepatide) and the once-daily oral Foundayo (orforglipron) — directly inside the Hims & Hers platform at self-pay prices.
Under the deal, Lilly gives Hims & Hers pharmacies direct access to its approved GLP-1 products. A patient can complete a consultation, receive a prescription if appropriate, and have the medicine shipped home without leaving the platform. Before the agreement, Lilly's obesity drugs were reachable through Hims & Hers only by leaving the site for LillyDirect, the manufacturer's own consumer channel.
Self-pay pricing starts at $149 per month for Foundayo and $299 for Zepbound. Hims & Hers shares rose about 8% on the news.
The structure mirrors the company's March 2026 arrangement with Novo Nordisk, which brought Wegovy and Ozempic onto the same platform — struck after Novo sued Hims & Hers over compounded versions of its drugs. Hims & Hers has said it never offered compounded copies of Lilly's GLP-1s and has committed not to do so.
Who Is Affected
- Cash-pay patients who previously had to choose between a branded prescription bought outside their telehealth subscription and a cheaper, unapproved alternative.
- Telehealth and compounding-adjacent sellers whose business model rested on the price gap between branded GLP-1s and compounded or "research" vials. A $149 oral and a $299 injectable narrow that gap considerably.
- Researchers and self-experimenters who buy peptides from gray-market suppliers: the deal makes the approved-product path cheaper and simpler, which changes the risk calculus rather than the pharmacology.
- Compounding pharmacies already operating under tighter FDA scrutiny, including the agency's recent 28-day beyond-use-date guidance for compounded GLP-1s.
Timeline
- April 1, 2026 — FDA approves Foundayo (orforglipron), the first non-peptide oral GLP-1, cleared in about 50 days.
- March 2026 — Hims & Hers begins selling Novo Nordisk's branded Wegovy and Ozempic, shifting away from compounded GLP-1s.
- October 2026 — Orforglipron clears cardiovascular safety in the ACHIEVE-4 trial; HHS drafts a policy easing enforcement on six compounded peptides.
- November 6, 2026 — Lilly–Hims & Hers agreement announced; branded Zepbound and Foundayo become orderable in-platform.
What This Means for Researchers
Two things change. First, the reference product is now trivially accessible at a published price, which weakens the case for buying unverified vials. Second, the market signal is unambiguous: manufacturers would rather route consumers through telehealth funnels than fight them, and they are pricing to compete with the gray market directly.
The practical consequence: the burden shifts to documentation. A prescription product arrives with a manufacturer, a lot number, and a regulatory paper trail. A research vial arrives with a label someone printed. The gap between those two experiences is now measured in dollars per month, not in access.
How to Verify Your Peptides
If you already hold a vial — compounded, imported, or sold as "research use only" — the verification steps do not change:
- Read how testing works before trusting any certificate of analysis.
- Understand the difference between HPLC and LC-MS, and why a purity percentage alone proves little.
- Check identity, purity, and fill weight — the three failures behind most bad vials.
- Review the testing FAQ for what a lab report should and should not contain.
Safe Alternatives
Approved, prescription-gated options are listed on our peptide reference pages, including tirzepatide and semaglutide. Vendor quality varies widely; our vendor directory records third-party testing status and documented complaints rather than marketing claims.
Sources
Industry reports; regulatory announcements; company statements.